Scientists at the Salk Institute have constructed the first comprehensive microprotein atlas of the human brain, revealing 1,067 previously unidentified microproteins linked to Alzheimer’s disease. This significant discovery marks an advancement in understanding the molecular mechanisms underlying brain aging and neurodegenerative conditions, as reported in the journal Nature Aging.
Understanding Microproteins
Microproteins, generally defined as proteins consisting of 150 amino acids or fewer, have eluded detection in previous brain studies due to their low abundance and the limitations of traditional mass spectrometry techniques. These molecules often reside alongside larger genes, making them difficult to detect in standard RNA sequencing workflows. The new atlas aims to fill the knowledge gap regarding these small proteins, which have been overlooked in past research, according to Dr. Alan Saghatelian, a senior author on the study.
The research team analyzed over 600 postmortem samples from the frontal cortex of older adults, including both healthy individuals and those with advanced Alzheimer’s. They utilized long-read sequencing and deep mass spectrometry data to analyze these samples, validating potential microprotein signatures through machine learning techniques.
Of particular interest, the researchers identified distinct dysregulation in microproteins across Alzheimer’s-affected brains. Microproteins from 39% of the tested transcripts showed fluctuations independent of their larger protein counterparts. Notably, one microprotein, micro-MKKS63, demonstrated a significant absence in Alzheimer’s tissue, where its parent protein was undetectable.
Expanding Research Horizons
This research emphasizes the limitations of focusing solely on traditional proteins in understanding complex diseases. Researchers argue that a broader comprehension of gene expression, including microproteins, is essential to uncovering the true biological drivers of neurodegenerative diseases. Dr. Brendan Miller, the first author of the study, highlighted the significance of a diverse range of gene products, stating that having a more comprehensive dataset will enhance the interpretation of gene functions in pathology.
Despite these advancements, challenges persist. Approximately 37% of actively expressed microproteins remain undetectable due to the limits of standard mass spectrometry. The researchers aim to further expand their atlas to other brain regions, utilizing larger patient cohorts to explore rare gene variants and identify new therapeutic targets for diseases like Alzheimer’s and Parkinson’s.
Why It Matters
The development of a microprotein atlas is a crucial step in unraveling the complexities of Alzheimer’s disease and other neurodegenerative conditions. By providing a more complete picture of brain proteins, this research could enable scientists to develop novel therapeutic strategies, ultimately contributing to improved understanding and treatment options for aging-related diseases.
